Calvin Sheng
Medical Student
Last active: 9/16/2013

Current stem cell delivery methods for myocardial repair.

Sheng CC, Zhou L, Hao J
Biomed Res Int. 2013 2013: 547902

PMID: 23509740 · PMCID: PMC3591183 · DOI:10.1155/2013/547902

Heart failure commonly results from an irreparable damage due to cardiovascular diseases (CVDs), the leading cause of morbidity and mortality in the United States. In recent years, the rapid advancements in stem cell research have garnered much praise for paving the way to novel therapies in reversing myocardial injuries. Cell types currently investigated for cellular delivery include embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cell lineages such as skeletal myoblasts, bone-marrow-derived stem cells (BMSCs), mesenchymal stem cells (MSCs), and cardiac stem cells (CSCs). To engraft these cells into patients' damaged myocardium, a variety of approaches (intramyocardial, transendocardial, transcoronary, venous, intravenous, intracoronary artery and retrograde venous administrations and bioengineered tissue transplantation) have been developed and explored. In this paper, we will discuss the pros and cons of these delivery modalities, the current state of their therapeutic potentials, and a multifaceted evaluation of their reported clinical feasibility, safety, and efficacy. While the issues of optimal delivery approach, the best progenitor stem cell type, the most effective dose, and timing of administration remain to be addressed, we are highly optimistic that stem cell therapy will provide a clinically viable option for myocardial regeneration.

MeSH Terms (13)

Animals Bone Marrow Cells Cardiovascular Diseases Embryonic Stem Cells Humans Myoblasts, Skeletal Myocardial Infarction Myocardium Pluripotent Stem Cells Regeneration Stem Cells Stem Cell Transplantation Wound Healing

Connections (1)

This publication is referenced by other Labnodes entities:

Links